Target of action of avatrombopag

Avatrombopag targets the thrombopoietin receptor (TPO-R). Thrombopoietin receptor is a receptor located on the surface of bone marrow cells. It binds to thrombopoietin (TPO) and regulates the production and release of platelets through signaling pathways. As a TPO-R agonist, avatrombopag can simulate the effects of TPO and combine with TPO-R to activate the signaling pathway of platelet production, promote the proliferation and maturation of platelet precursor cells in the bone marrow, thereby increasing the number of platelets. This mechanism of action makes avatrombopag one of the effective drugs for the treatment of idiopathic thrombocytopenic purpura (ITP), which can increase the patient's platelet count and prevent or reduce bleeding symptoms.